TY - THES A1 - Grimm, Anne Rosemarie T1 - Prognostische Determinanten im kardiogenen und septischen Schock T1 - Prognostic determinants of cardiogenic and septic shock N2 - In diese monozentrische retrospektive Studie eingeschlossen wurden insgesamt 132 Patienten mit Schock, darunter 75 Patienten mit kardiogenem- und 57 Patienten mit septischem Schock. Um potentielle Prädiktoren für die Krankenhaussterblichkeit zu finden, wurden folgende Paramater untersucht: Alter, Geschlecht, BMI, kardiovaskuläre Risikofaktoren und Vorerkrankungen, Vitalparameter bei Aufnahme inkl. Schockindex, laborchemische Parameter inkl. BGA, maximaler Laktatanstieg im Verlauf, Interventionen inklusive Reanimation, Beatmung, Akutrevaskularisation und Anlage von mechanischen Kreislaufunterstützungssystemen, Katecholamintherapie und hämodynamisches Monitoring mit dem PiCCO-Verfahren. Hauptergebnis unserer Studie ist eine erhebliche Krankenhaussterblichkeit von 50% bei einem mittleren Aufenthalt von 14 Tagen ohne signifikanten Unterschied zwischen kardiogenem- (45%) und septischem Schock (55%), obgleich Patienten mit kardiogenem Schock signifikant älter und häufiger kardiovaskulär vorerkrankt waren. Prädiktoren für die Krankenhaussterblichkeit waren bei Patienten mit kardiogenem Schock die Höhe des maximalen Laktatanstiegs, das Auftreten eines akuten Nierenversagens, die Höhe der Transaminasen als Marker einer Schockleber, die fehlende Möglichkeit einer Akutrevaskularisation und die Höhe des Troponins als Marker für das Ausmaß des Myokardschadens. Prädiktoren für die Krankenhaussterblichkeit im septischen Schock waren ebenfalls die Höhe des maximalen Laktatanstiegs, die Notwendigkeit einer Reanimation, sowie Höhe des ELWI. Die übrigen klinischen, laborchemischen und hämodynamischen Parameter waren weder beim kardiogenen- noch beim septischen Schock prädiktiv für die Mortalität. Die beste Strategie zur Senkung der hohen Mortalität beider Schockformen besteht in der Prophylaxe des jeweiligen Schockgeschehens. Bei bereits in Gang gesetzten Circulus vitiosus, müssen zukünftige Studien klären, welches hämodynamische Monitoring zusammen mit klinischen Befunden und ggf. Bildgebung ein optimiertes Volumen- und Katecholamin-Management erlaubt. Bei Patienten mit kardiogenem Schock bleibt zu klären, ob die in unserer Studie gefundene erhebliche Krankenhaussterblichkeit von 45% durch den gezielten Einsatz moderner, perkutan implantierbarer Kreislaufunterstützungssysteme gebessert werden kann. Bei Patienten mit septischem Schock ist insbesondere bei pneumogener Sepsis das rechtzeitige Erkennen und die Therapie eines ARDS eine bleibende Herausforderung. Zukünftige Studien an größeren Patientenkollektiven müssen klären, ob die Bestimmung des ELWI mit dem PiCCO-Verfahren hilfreich ist, die Entstehung eines ARDS frühzeitig erkennen und behandeln zu können. N2 - A total of 132 patients with shock were included in this retrospective monocenter study including 75 patients with cardiogenic shock and 57 patients with septic shock. The mean age of the 132 patients was 64 ± 14 years. In order to detect potential predictors for in hospital mortality of patients with cardiogenic shock and septic shock, the following parameters were analysed: age, gender, BMI, cardiovascular risk factors and pre-existing diseases, vital parameters at hospital admission including serum lactate, maximum lactate increase, interventions at hospital admission and thereafter including resuscitation, non-invasive and invasive ventilation, catecholamine therapy and hemodynamic monitoring using the PICCO-system. The major finding of our study was a considerable in-hospital mortality of 50% during a mean hospital stay of 14 days without a significant difference between patients with cardiogenic shock (45%) and patients with septic shock (55%), although patients with cardiogenic shock were significantly older and had a higher prevalence of pre-existing cardiovascular diseases compared to patients with septic shock. Predictors for the in-hospital mortality of patients with cardiogenic shock included maximum serum lactate levels, occurrence of acute renal failure, maximum elevations in serum transaminases as indicator for shock liver, absent possibility of acute myocardial revascularisation and troponin levels at hospital admission as marker for the extent of myocardial injury. Predictors of in hospital mortality in patients with septic shock also included maximum serum lactate levels, need to resuscitate during sepsis as well as extravascular lung-water index (EVLWI). None of the remaining clinical, laboratory and hemodynamic variables predicted mortality in cardiogenic shock or septic shock. The best strategy to decrease the high mortality of cardiogenic shock and septic shock is prevention of these shock entities. For those patients, in whom the vicious circle of shock development has already started, future studies need to clarify, which kind of hemodynamic monitoring combined with clinical findings including bedside echocardiography allows for optimized volume and catecholamine management. For patients with cardiogenic shock, it remains to be clarified whether the considerable in-hospital mortality of 45% in our study can be improved using modern percutaneous implantable cardiovascular assist devices. In patients with septic shock and particularly in patients with pneumogenic shock, early recognition and therapy of ARDS remains to be a challenge. Future studies including large patient cohorts need to clarify whether determination of extravascular lung-water index using the PiCCO system helps to detect and treat a developing ARDS at an early stage. KW - Schock KW - Kardiogener Schock KW - Septischer Schock Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-369953 ER - TY - JOUR A1 - Kurabi, Arwa A1 - Schaerer, Daniel A1 - Noack, Volker A1 - Bernhardt, Marlen A1 - Pak, Kwang A1 - Alexander, Thomas A1 - Husseman, Jacob A1 - Nguyen, Quyen A1 - Harris, Jeffrey P. A1 - Ryan, Allen F. T1 - Active Transport of Peptides Across the Intact Human Tympanic Membrane JF - Scientific Reports N2 - We previously identified peptides that are actively transported across the intact tympanic membrane (TM) of rats with infected middle ears. To assess the possibility that this transport would also occur across the human TM, we first developed and validated an assay to evaluate transport in vitro using fragments of the TM. Using this assay, we demonstrated the ability of phage bearing a TM-transiting peptide to cross freshly dissected TM fragments from infected rats or from uninfected rats, guinea pigs and rabbits. We then evaluated transport across fragments of the human TM that were discarded during otologic surgery. Human trans-TM transport was similar to that seen in the animal species. Finally, we found that free peptide, unconnected to phage, was transported across the TM at a rate comparable to that seen for peptide-bearing phage. These studies provide evidence supporting the concept of peptide-mediated drug delivery across the intact TM and into the middle ears of patients. KW - assay systems KW - biological models Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-230929 VL - 8 ER - TY - JOUR A1 - Hommers, L. G. A1 - Richter, J. A1 - Yang, Y. A1 - Raab, A. A1 - Baumann, C. A1 - Lang, K. A1 - Schiele, M. A. A1 - Weber, H. A1 - Wittmann, A. A1 - Wolf, C. A1 - Alpers, G. W. A1 - Arolt, V. A1 - Domschke, K. A1 - Fehm, L. A1 - Fydrich, T. A1 - Gerlach, A. A1 - Gloster, A. T. A1 - Hamm, A. O. A1 - Helbig-Lang, S. A1 - Kircher, T. A1 - Lang, T. A1 - Pané-Farré, C. A. A1 - Pauli, P. A1 - Pfleiderer, B. A1 - Reif, A. A1 - Romanos, M. A1 - Straube, B. A1 - Ströhle, A. A1 - Wittchen, H.-U. A1 - Frantz, S. A1 - Ertl, G. A1 - Lohse, M. J. A1 - Lueken, U. A1 - Deckert, J. T1 - A functional genetic variation of SLC6A2 repressor hsa-miR-579-3p upregulates sympathetic noradrenergic processes of fear and anxiety JF - Translational Psychiatry N2 - Increased sympathetic noradrenergic signaling is crucially involved in fear and anxiety as defensive states. MicroRNAs regulate dynamic gene expression during synaptic plasticity and genetic variation of microRNAs modulating noradrenaline transporter gene (SLC6A2) expression may thus lead to altered central and peripheral processing of fear and anxiety. In silico prediction of microRNA regulation of SLC6A2 was confirmed by luciferase reporter assays and identified hsa-miR-579-3p as a regulating microRNA. The minor (T)-allele of rs2910931 (MAFcases = 0.431, MAFcontrols = 0.368) upstream of MIR579 was associated with panic disorder in patients (pallelic = 0.004, ncases = 506, ncontrols = 506) and with higher trait anxiety in healthy individuals (pASI = 0.029, pACQ = 0.047, n = 3112). Compared to the major (A)-allele, increased promoter activity was observed in luciferase reporter assays in vitro suggesting more effective MIR579 expression and SLC6A2 repression in vivo (p = 0.041). Healthy individuals carrying at least one (T)-allele showed a brain activation pattern suggesting increased defensive responding and sympathetic noradrenergic activation in midbrain and limbic areas during the extinction of conditioned fear. Panic disorder patients carrying two (T)-alleles showed elevated heart rates in an anxiety-provoking behavioral avoidance test (F(2, 270) = 5.47, p = 0.005). Fine-tuning of noradrenaline homeostasis by a MIR579 genetic variation modulated central and peripheral sympathetic noradrenergic activation during fear processing and anxiety. This study opens new perspectives on the role of microRNAs in the etiopathogenesis of anxiety disorders, particularly their cardiovascular symptoms and comorbidities. KW - clinical genetics KW - psychiatric disorders Y1 - 2018 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-322497 VL - 8 ER - TY - THES A1 - Göttler [geb. Lang], Anna T1 - Auswirkung der bariatrischen Operation auf die Aktivität des autonomen Nervensystems im kardialen und peripheren Kompartiment T1 - Effect of bariatric surgery on autonomic nervous system activity in the cardiac and peripheral compartment of the body N2 - Die vorliegende Arbeit thematisiert die Aktivität des autonomen Nervensystems im Vergleich vor versus nach bariatrischer Operation bei ProbandInnen mit morbider Adipositas. Wir untersuchten, ob die Operation und der damit einhergehende Gewichtsverlust drei Monate nach dem bariatrischen Eingriff zu einer Veränderung der Aktivität des autonomen Nervensystems im thorakalen und im motorischen/peripheren Kompartiment führt. Als Parameter dienen für das thorakale Kompartiment die Herzfrequenzvariabilität und für das periphere/motorische Kompartiment vaskuläre (lnRHI und AI) und sudomotorische (Schweißvolumen, Antwortlatenz) Parameter. Unsere Ergebnisse im thorakalen Kompartiment zeigen einen Anstieg der Herzfrequenzvariabilität 3 Monate nach bariatrischer Operation. Wir schließen uns daher der Hypothese an, die mit morbider Adipositas assoziierte Erhöhung der sympathischen Aktivität im thorakalen Kompartiment könne durch bariatrische Operationen reversibel sein. Im peripheren/motorischen Kompartiment können wir keine eindeutige Veränderung der Aktivität des autonomen Nervensystems vor versus nach bariatrischer Operation beobachten. Andere Studien konnten hierzu deutlichere Ergebnisse erheben, die ebenfalls eine erhöhte sympathische Aktivität im motorischen Kompartiment zeigten, welche nach bariatrischer Operation reversibel war. Insgesamt können wir die These einer autonomen Imbalance bei Adipositas sowie einer Verringerung der sympathischen Aktivität im thorakalen Kompartiment nach bariatrischer Operation unterstützen. Die Veränderungen im autonomen Nervensystem leisten möglicherweise einen Beitrag zur Verbesserung der kardiovaskulären Gesundheit und der metabolischen Situation nach der bariatrischen Operation. N2 - The present work addresses the activity of the autonomic nervous system comparing before versus after bariatric surgery in subjects with morbid obesity. We investigated whether surgery and associated weight loss led to changes in autonomic nervous system activity in the thoracic and motoric/peripheral compartment three months after bariatric surgery. Heart rate variability serves as parameter for the thoracic compartment, vascular (lnRHI and AI) and sudomotor (sweat volume, response latency) parameters for the peripheral/motoric compartment. Our results in the thoracic compartment show an increase in heart rate variability 3 months after bariatric surgery. We therefore agree with the hypothesis that the increase in sympathetic activity in the thoracic compartment associated with morbid obesity could be reversible by bariatric surgery. In the peripheral/motoric compartment, we did not observe any clear change in autonomic nervous system activity comparing before versus after bariatric surgery. Other studies were able to obtain clearer results showing increased sympathetic activity in the motoric compartment in subjects with morbid obesity that was reversible after bariatric surgery. Overall, we can support the hypothesis of an autonomic imbalance in obesity and a reduction in sympathetic activity in the thoracic compartment after bariatric surgery. The changes in the autonomic nervous system may contribute to improving cardiovascular health and metabolic status after bariatric surgery. KW - Vegetatives Nervensystem KW - Gefäßwiderstand KW - Herzfrequenzvariabilität KW - quantitativer sudomotorischer Axonreflextest KW - endotheliale Funktion KW - Adipositas KW - autonomes Nervensystem KW - Frequenzbereich KW - Zeitbereich KW - bariatrische KW - Fettsucht Y1 - 2024 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-369328 ER - TY - JOUR A1 - Li, Minghao A1 - Pamporaki, Christina A1 - Fliedner, Stephanie M. J. A1 - Timmers, Henri J. L. M. A1 - Nölting, Svenja A1 - Beuschlein, Felix A1 - Prejbisz, Aleksander A1 - Remde, Hanna A1 - Robledo, Mercedes A1 - Bornstein, Stefan R. A1 - Lenders, Jacques W. M. A1 - Eisenhofer, Graeme A1 - Bechmann, Nicole T1 - Metastatic pheochromocytoma and paraganglioma: signs and symptoms related to catecholamine secretion JF - Discover Oncology N2 - Background The presence or future development of metastatic pheochromocytomas or paragangliomas (mPPGLs) can be difficult to diagnose or predict at initial presentation. Since production of catecholamines from mPPGLs is different from non-metastatic tumors (non-mPPGLs), this study aimed to clarify whether presenting catecholamine-related signs and symptoms (cSS) might also differ. Methods The study included 249 patients, 43 with mPPGL and 206 with non-mPPGL. Clinical data at the time of biochemical diagnosis (i.e. at entry into the study) were used to generate a cumulative score of cSS for each patient. Results Patients with mPPGL were significantly younger (43.3 ± 14 vs. 48.9 ± 16.1 years) and included a lower proportion of females (39.5% vs. 60.7%) than patients with non-mPPGLs. Frequencies of signs and symptoms did not differ between the two groups. Patients with mPPGLs had lower (P < 0.001) urinary excretion of epinephrine (3.5 (IQR, 1.9—6.5) µg/day) than those with non-mPPGLs (19.1 (IQR, 4.3—70.2) µg/day). There was no difference in urinary excretion of norepinephrine. In patients with mPPGLs a high cSS score was associated with high urinary excretion of norepinephrine and normetanephrine. In contrast, in patients with non-mPPGLs, a high cSS was associated with high urinary excretion of epinephrine and metanephrine. Conclusion Although presenting signs and symptoms were associated with production of norepinephrine in patients with mPPGLs and of epinephrine in patients with non-mPPGLs, there were no differences in signs and symptoms between the two groups. Therefore, consideration of signs and symptoms does not appear helpful for distinguishing patients with and without mPPGLs. KW - pheochromocytoma KW - paraganglioma KW - metastatic KW - signs KW - symptoms KW - catecholamines Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-309901 SN - 2730-6011 VL - 12 ER - TY - JOUR A1 - Minner, S. A1 - Schreiner, J. A1 - Saeger, W. T1 - Adrenal cancer: relevance of different grading systems and subtypes JF - Clinical and Translational Oncology N2 - Purpose The subclassification of adrenal cancers according to the WHO classification in ordinary, myxoid, oncocytic, and sarcomatoid as well as pediatric types is well established, but the criteria for each subtype are not sufficiently determined and the relative frequency of the different types of adrenal cancers has not been studied in large cohorts. Therefore, our large collection of surgically removed adrenal cancers should be reviewed o establish the criteria for the subtypes and to find out the frequency of the various types. Methods In our series of 521 adrenal cancers the scoring systems of Weiss et al., Hough et al., van Slooten et al. and the new Helsinki score system were used for the ordinary type of cancer (97% of our series) and the myxoid type (0.8%). For oncocytic carcinomas (2%), the scoring system of Bisceglia et al. was applied. Results Discrepancies between benign and malignant diagnoses from the first thee classical scoring systems are not rare (22% in our series) and could be resolved by the Helsinki score especially by Ki-67 index (more than 8% unequivocally malignant). Since all our cancer cases are positive in the Helsinki score, this system can replace the three elder systems. For identification of sarcomatoid cancer as rarest type in our series (0.2%), the scoring systems are not practical but additional immunostainings used for soft tissue tumors and in special cases molecular pathology are necessary to differentiate these cancers from adrenal sarcomas. According to the relative frequencies of the different subtypes of adrenal cancers the main type is the far most frequent (97%) followed by the oncocytic type (2%), the myxoid type (0.8%) and the very rare sarcomatoid type (0.2%). Conclusions The Helsinki score is the best for differentiating adrenal carcinomas of the main, the oncocytic, and the myxoid type in routine work. Additional scoring systems for these carcinomas are generally not any longer necessary. Signs of proliferation (mitoses and Ki-67 index) and necroses are the most important criteria for diagnosis of malignancy. KW - adrenal KW - cancer KW - cancer types KW - classification Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-308479 SN - 1699-048X SN - 1699-3055 VL - 23 IS - 7 ER - TY - JOUR A1 - Adolf, Christian A1 - Braun, Leah T. A1 - Fuss, Carmina T. A1 - Hahner, Stefanie A1 - Künzel, Heike A1 - Handgriff, Laura A1 - Sturm, Lisa A1 - Heinrich, Daniel A. A1 - Schneider, Holger A1 - Bidlingmaier, Martin A1 - Reincke, Martin T1 - Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism JF - Endocrine N2 - Context Primary aldosteronism (PA) is the most frequent form of endocrine hypertension. Besides its deleterious impact on cardiovascular target organ damage, PA is considered to cause osteoporosis. Patients and methods We assessed bone turnover in a subset of 36 postmenopausal women with PA. 18 patients had unilateral PA and were treated by adrenalectomy, whereas 18 patients had bilateral PA and received mineralocorticoid receptor antagonist (MRA) therapy respectively. 18 age- and BMI-matched females served as controls. To estimate bone remodeling, we measured the bone turnover markers intact procollagen 1 N-terminal propeptide, bone alkaline phosphatase, osteocalcin and tartrate resistant acid phosphatase 5b in plasma by chemiluminescent immunoassays at time of diagnosis and one year after initiation of treatment. Study design Observational longitudinal cohort study. Setting Tertiary care hospital. Results Compared with controls, patients with PA had mildly elevated osteocalcin at baseline (p = 0.013), while the other bone markers were comparable between both groups. There were no differences between the unilateral and the bilateral PA subgroup. One year after initiation of MRA treatment with spironolactone bone resorption and bone formation markers had significantly decreased in patients with bilateral PA. In contrast, patients adrenalectomized because of unilateral PA showed no significant change of bone turnover markers. Conclusion This study shows that aldosterone excess in postmenopausal women with PA is not associated with a relevant increase of bone turnover markers at baseline. However, we observed a significant decrease of bone markers in patients treated with spironolactone, but not in patients treated by adrenalectomy. KW - aldosterone KW - osteocalcin KW - osteoporosis KW - hyperparathyroidism KW - cortisol Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-315966 SN - 1355-008X SN - 1559-0100 VL - 69 IS - 3 ER - TY - JOUR A1 - Bliziotis, Nikolaos G. A1 - Kluijtmans, Leo A. J. A1 - Soto, Sebastian A1 - Tinnevelt, Gerjen H. A1 - Langton, Katharina A1 - Robledo, Mercedes A1 - Pamporaki, Christina A1 - Engelke, Udo F. H. A1 - Erlic, Zoran A1 - Engel, Jasper A1 - Deutschbein, Timo A1 - Nölting, Svenja A1 - Prejbisz, Aleksander A1 - Richter, Susan A1 - Prehn, Cornelia A1 - Adamski, Jerzy A1 - Januszewicz, Andrzej A1 - Reincke, Martin A1 - Fassnacht, Martin A1 - Eisenhofer, Graeme A1 - Beuschlein, Felix A1 - Kroiss, Matthias A1 - Wevers, Ron A. A1 - Jansen, Jeroen J. A1 - Deinum, Jaap A1 - Timmers, Henri J. L. M. T1 - Pre- versus post-operative untargeted plasma nuclear magnetic resonance spectroscopy metabolomics of pheochromocytoma and paraganglioma JF - Endocrine N2 - Purpose Pheochromocytomas and Paragangliomas (PPGL) result in chronic catecholamine excess and serious health complications. A recent study obtained a metabolic signature in plasma from PPGL patients; however, its targeted nature may have generated an incomplete picture and a broader approach could provide additional insights. We aimed to characterize the plasma metabolome of PPGL patients before and after surgery, using an untargeted approach, and to broaden the scope of the investigated metabolic impact of these tumors. Design A cohort of 36 PPGL patients was investigated. Blood plasma samples were collected before and after surgical tumor removal, in association with clinical and tumor characteristics. Methods Plasma samples were analyzed using untargeted nuclear magnetic resonance (NMR) spectroscopy metabolomics. The data were evaluated using a combination of uni- and multi-variate statistical methods. Results Before surgery, patients with a nonadrenergic tumor could be distinguished from those with an adrenergic tumor based on their metabolic profiles. Tyrosine levels were significantly higher in patients with high compared to those with low BMI. Comparing subgroups of pre-operative samples with their post-operative counterparts, we found a metabolic signature that included ketone bodies, glucose, organic acids, methanol, dimethyl sulfone and amino acids. Three signals with unclear identities were found to be affected. Conclusions Our study suggests that the pathways of glucose and ketone body homeostasis are affected in PPGL patients. BMI-related metabolite levels were also found to be altered, potentially linking muscle atrophy to PPGL. At baseline, patient metabolomes could be discriminated based on their catecholamine phenotype. KW - PPGL KW - metabolomics KW - NMR KW - paired KW - plasma KW - operation Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-326574 VL - 75 IS - 1 ER - TY - JOUR A1 - Nowotny, Hanna A1 - Ahmed, S. Faisal A1 - Bensing, Sophie A1 - Beun, Johan G. A1 - Brösamle, Manuela A1 - Chifu, Irina A1 - Claahsen van der Grinten, Hedi A1 - Clemente, Maria A1 - Falhammar, Henrik A1 - Hahner, Stefanie A1 - Husebye, Eystein A1 - Kristensen, Jette A1 - Loli, Paola A1 - Lajic, Svetlana A1 - Reisch, Nicole T1 - Therapy options for adrenal insufficiency and recommendations for the management of adrenal crisis JF - Endocrine N2 - Adrenal insufficiency (AI) is a life-threatening condition requiring life-long glucocorticoid (GC) substitution therapy, as well as stress adaptation to prevent adrenal crises. The number of individuals with primary and secondary adrenal insufficiency in Europe is estimated to be 20–50/100.000. A growing number of AI cases are due to side effects of GC treatment used in different treatment strategies for cancer and to immunotherapy in cancer treatment. The benefit of hormone replacement therapy is evident but long-term adverse effects may arise due to the non-physiological GC doses and treatment regimens used. Given multiple GC replacement formulations available comprising short-acting, intermediate, long-acting and novel modified-release hydrocortisone as well as subcutaneous formulations, this review offers a concise summary on the latest therapeutic improvements for treatment of AI and prevention of adrenal crises. As availability of various glucocorticoid formulations and access to expert centers across Europe varies widely, European Reference Networks on rare endocrine conditions aim at harmonizing treatment and ensure access to specialized patient care for individual case-by-case treatment decisions. To improve the availability across Europe to cost effective oral and parenteral formulations of hydrocortisone will save lives. KW - adrenal insufficiency KW - congenital adrenal hyperplasia KW - adrenal crisis KW - glucocorticoid replacement KW - hydrocortisone KW - stress instructions Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-308769 SN - 1355-008X SN - 1559-0100 VL - 71 IS - 3 ER - TY - JOUR A1 - Amereller, Felix A1 - Deutschbein, Timo A1 - Joshi, Mamta A1 - Schopohl, Jochen A1 - Schilbach, Katharina A1 - Detomas, Mario A1 - Duffy, Leo A1 - Carroll, Paul A1 - Papa, Sophie A1 - Störmann, Sylvère T1 - Differences between immunotherapy-induced and primary hypophysitis—a multicenter retrospective study JF - Pituitary N2 - Objective Immune checkpoint inhibitors can cause various immune-related adverse events including secondary hypophysitis. We compared clinical characteristics of immunotherapy-induced hypophysitis (IIH) and primary hypophysitis (PH) Design Retrospective multicenter cohort study including 56 patients with IIH and 60 patients with PH. Methods All patients underwent extensive endocrine testing. Data on age, gender, symptoms, endocrine dysfunction, MRI, immunotherapeutic agents and autoimmune diseases were collected. Results Median time of follow-up was 18 months in IIH and 69 months in PH. The median time from initiation of immunotherapy to IIH diagnosis was 3 months. IIH affected males more frequently than PH (p < 0.001) and led to more impaired pituitary axes in males (p < 0.001). The distribution of deficient adenohypophysial axes was comparable between both entities, however, central hypocortisolism was more frequent (p < 0.001) and diabetes insipidus considerably less frequent in IIH (p < 0.001). Symptoms were similar except that visual impairment occurred more rarely in IIH (p < 0.001). 20 % of IIH patients reported no symptoms at all. Regarding MRI, pituitary stalk thickening was less frequent in IIH (p = 0.009). Concomitant autoimmune diseases were more prevalent in PH patients before the diagnosis of hypophysitis (p = 0.003) and more frequent in IIH during follow-up (p = 0.002). Conclusions Clinically, IIH and PH present with similar symptoms. Diabetes insipidus very rarely occurs in IIH. Central hypocortisolism, in contrast, is a typical feature of IIH. Preexisting autoimmunity seems not to be indicative of developing IIH. KW - primary hypophysitis KW - immunotherapy-induced hypophysitis KW - checkpoint inhibitors KW - immune-related adverse events KW - pembrolizumab KW - ipilimumab KW - nivolumab Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-308704 SN - 1386-341X SN - 1573-7403 VL - 25 IS - 1 ER -